Unable to connect, retrying...
Online collaborative whiteboard. Powerful, engaging with timer, emoji's, commenting and voting.
Search for RSS feeds

U.S. Supreme Court Decision Upholds Implied Certification Theory of False Claims Act Liability, Articulates New Limits

Last month, Lindsey provided readers of the Drug and Device Law blog with an overview of United Health Services, Inc. v. U.S. ex rel. Escobar, a False Claims Act (FCA) case that was bringing the...

https://www.lifescienceslegalupdate.com/2016/06/articles/health-care/fraud-abuse/u-s-supreme-court-decision-upholds-implied-certification-theory-of-false-claims-act-liability-articulates-new-limits/

U.S. Supreme Court Ruling Addresses Wartime Tolling of Statute of Limitations Under False Claims Act

On May 26, the U.S. Supreme Court issued its ruling in Kellogg Brown & Root Services, Inc. v. United States ex rel Carter, No. 12-1497, __ S. Ct. __ (2015), in which a relator brought civil False...

https://www.lifescienceslegalupdate.com/2015/05/articles/regulatory-developments/u-s-supreme-court-ruling-addresses-wartime-tolling-of-statute-of-limitations-under-false-claims-act/

Supreme Court Invites Solicitor General Weigh In on Cert Petition Involving Specificity of False Claims Act Complaints

On October 7, 2013, in evaluating a pending cert petition, the U.S. Supreme Court invited the Office of Solicitor General to provide its views regarding the level of specificity required when all...

https://www.lifescienceslegalupdate.com/2013/10/articles/health-care/supreme-court-invites-solicitor-general-weigh-in-on-cert-petition-involving-specificity-of-false-claims-act-complaints/

Supreme Court Decision on Reverse Payments has Significant Implications for Pharmaceutical Manufacturers

Reed Smith’s Global Regulatory Enforcement Law Blog recently featured a detailed analysis of the Supreme Court’s decision in FTC v. Actavis, where the court ruled five-to-three that reverse p...

https://www.lifescienceslegalupdate.com/2013/06/articles/industry-developments/supreme-court-decision-on-reverse-payments-has-significant-implications-for-pharmaceutical-manufacturers/